Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury

Viswanathan Natarajan, Steven M. Dudek, Jeffrey R. Jacobson, Liliana Moreno-Vinasco, Long Shuang Huang, Taimur Abassi, Biji Mathew, Yutong Zhao, Lichun Wang, Robert Bittman, Ralph Weichselbaum, Evgeny Berdyshev, Joe GN Garcia

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Acute lung injury (ALI) attributable to sepsis or mechanical ventilation and subacute lung injury because of ionizing radiation (RILI) share profound increases in vascular permeability as a key element and a common pathway driving increased morbidity and mortality. Unfortunately, despite advances in the understanding of lung pathophysiology, specific therapies do not yet exist for the treatment of ALI or RILI, or for the alleviation of unremitting pulmonary leakage, which serves as a defining feature of the illness. A critical need exists for new mechanistic insights that can lead to novel strategies, biomarkers, and therapies to reduce lung injury. Sphingosine 1-phosphate (S1P) is a naturally occurring bioactive sphingolipid that acts extracellularly via its G protein-coupled S1P1-5 as well as intracellularly on various targets. S1P-mediated cellular responses are regulated by the synthesis of S1P, catalyzed by sphingosine kinases 1 and 2, and by the degradation of S1P mediated by lipid phosphate phosphatases, S1P phosphatases, and S1P lyase. We and othershave demonstratedthatS1P is a potent angiogenic factor that enhances lung endothelial cell integrity and an inhibitor of vascular permeability and alveolar flooding in preclinical animal models of ALI. In addition to S1P, S1P analogues such as 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720), FTY720 phosphate, and FTY720 phosphonates offer therapeutic potential in murine models of lung injury. This translational review summarizes the roles of S1P, S1P analogues, S1P-metabolizing enzymes, and S1P receptors in the pathophysiology of lung injury, with particular emphasis on the development of potential novel biomarkers and S1P-based therapies for ALI and RILI.

Original languageEnglish (US)
Pages (from-to)6-17
Number of pages12
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume49
Issue number1
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Lysosphingolipid Receptors
Acute Lung Injury
Lung Injury
Capillary Permeability
Biomarkers
Lung
sphingosine 1-phosphate
Fingolimod Hydrochloride
Therapeutics
Organophosphonates
Sphingolipids
Angiogenesis Inducing Agents
Ionizing radiation
Endothelial cells
Ionizing Radiation
Artificial Respiration
GTP-Binding Proteins
Sepsis
Animals
Endothelial Cells

Keywords

  • S1P lyase
  • S1P receptors
  • Sepsis
  • Sphingolipids
  • Sphingosine kinase

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury. / Natarajan, Viswanathan; Dudek, Steven M.; Jacobson, Jeffrey R.; Moreno-Vinasco, Liliana; Huang, Long Shuang; Abassi, Taimur; Mathew, Biji; Zhao, Yutong; Wang, Lichun; Bittman, Robert; Weichselbaum, Ralph; Berdyshev, Evgeny; Garcia, Joe GN.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 49, No. 1, 07.2013, p. 6-17.

Research output: Contribution to journalArticle

Natarajan, V, Dudek, SM, Jacobson, JR, Moreno-Vinasco, L, Huang, LS, Abassi, T, Mathew, B, Zhao, Y, Wang, L, Bittman, R, Weichselbaum, R, Berdyshev, E & Garcia, JGN 2013, 'Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury', American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 1, pp. 6-17. https://doi.org/10.1165/rcmb.2012-0411TR
Natarajan, Viswanathan ; Dudek, Steven M. ; Jacobson, Jeffrey R. ; Moreno-Vinasco, Liliana ; Huang, Long Shuang ; Abassi, Taimur ; Mathew, Biji ; Zhao, Yutong ; Wang, Lichun ; Bittman, Robert ; Weichselbaum, Ralph ; Berdyshev, Evgeny ; Garcia, Joe GN. / Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury. In: American Journal of Respiratory Cell and Molecular Biology. 2013 ; Vol. 49, No. 1. pp. 6-17.
@article{b0f0e7db224148478cc3e37a0617bea4,
title = "Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury",
abstract = "Acute lung injury (ALI) attributable to sepsis or mechanical ventilation and subacute lung injury because of ionizing radiation (RILI) share profound increases in vascular permeability as a key element and a common pathway driving increased morbidity and mortality. Unfortunately, despite advances in the understanding of lung pathophysiology, specific therapies do not yet exist for the treatment of ALI or RILI, or for the alleviation of unremitting pulmonary leakage, which serves as a defining feature of the illness. A critical need exists for new mechanistic insights that can lead to novel strategies, biomarkers, and therapies to reduce lung injury. Sphingosine 1-phosphate (S1P) is a naturally occurring bioactive sphingolipid that acts extracellularly via its G protein-coupled S1P1-5 as well as intracellularly on various targets. S1P-mediated cellular responses are regulated by the synthesis of S1P, catalyzed by sphingosine kinases 1 and 2, and by the degradation of S1P mediated by lipid phosphate phosphatases, S1P phosphatases, and S1P lyase. We and othershave demonstratedthatS1P is a potent angiogenic factor that enhances lung endothelial cell integrity and an inhibitor of vascular permeability and alveolar flooding in preclinical animal models of ALI. In addition to S1P, S1P analogues such as 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720), FTY720 phosphate, and FTY720 phosphonates offer therapeutic potential in murine models of lung injury. This translational review summarizes the roles of S1P, S1P analogues, S1P-metabolizing enzymes, and S1P receptors in the pathophysiology of lung injury, with particular emphasis on the development of potential novel biomarkers and S1P-based therapies for ALI and RILI.",
keywords = "S1P lyase, S1P receptors, Sepsis, Sphingolipids, Sphingosine kinase",
author = "Viswanathan Natarajan and Dudek, {Steven M.} and Jacobson, {Jeffrey R.} and Liliana Moreno-Vinasco and Huang, {Long Shuang} and Taimur Abassi and Biji Mathew and Yutong Zhao and Lichun Wang and Robert Bittman and Ralph Weichselbaum and Evgeny Berdyshev and Garcia, {Joe GN}",
year = "2013",
month = "7",
doi = "10.1165/rcmb.2012-0411TR",
language = "English (US)",
volume = "49",
pages = "6--17",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury

AU - Natarajan, Viswanathan

AU - Dudek, Steven M.

AU - Jacobson, Jeffrey R.

AU - Moreno-Vinasco, Liliana

AU - Huang, Long Shuang

AU - Abassi, Taimur

AU - Mathew, Biji

AU - Zhao, Yutong

AU - Wang, Lichun

AU - Bittman, Robert

AU - Weichselbaum, Ralph

AU - Berdyshev, Evgeny

AU - Garcia, Joe GN

PY - 2013/7

Y1 - 2013/7

N2 - Acute lung injury (ALI) attributable to sepsis or mechanical ventilation and subacute lung injury because of ionizing radiation (RILI) share profound increases in vascular permeability as a key element and a common pathway driving increased morbidity and mortality. Unfortunately, despite advances in the understanding of lung pathophysiology, specific therapies do not yet exist for the treatment of ALI or RILI, or for the alleviation of unremitting pulmonary leakage, which serves as a defining feature of the illness. A critical need exists for new mechanistic insights that can lead to novel strategies, biomarkers, and therapies to reduce lung injury. Sphingosine 1-phosphate (S1P) is a naturally occurring bioactive sphingolipid that acts extracellularly via its G protein-coupled S1P1-5 as well as intracellularly on various targets. S1P-mediated cellular responses are regulated by the synthesis of S1P, catalyzed by sphingosine kinases 1 and 2, and by the degradation of S1P mediated by lipid phosphate phosphatases, S1P phosphatases, and S1P lyase. We and othershave demonstratedthatS1P is a potent angiogenic factor that enhances lung endothelial cell integrity and an inhibitor of vascular permeability and alveolar flooding in preclinical animal models of ALI. In addition to S1P, S1P analogues such as 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720), FTY720 phosphate, and FTY720 phosphonates offer therapeutic potential in murine models of lung injury. This translational review summarizes the roles of S1P, S1P analogues, S1P-metabolizing enzymes, and S1P receptors in the pathophysiology of lung injury, with particular emphasis on the development of potential novel biomarkers and S1P-based therapies for ALI and RILI.

AB - Acute lung injury (ALI) attributable to sepsis or mechanical ventilation and subacute lung injury because of ionizing radiation (RILI) share profound increases in vascular permeability as a key element and a common pathway driving increased morbidity and mortality. Unfortunately, despite advances in the understanding of lung pathophysiology, specific therapies do not yet exist for the treatment of ALI or RILI, or for the alleviation of unremitting pulmonary leakage, which serves as a defining feature of the illness. A critical need exists for new mechanistic insights that can lead to novel strategies, biomarkers, and therapies to reduce lung injury. Sphingosine 1-phosphate (S1P) is a naturally occurring bioactive sphingolipid that acts extracellularly via its G protein-coupled S1P1-5 as well as intracellularly on various targets. S1P-mediated cellular responses are regulated by the synthesis of S1P, catalyzed by sphingosine kinases 1 and 2, and by the degradation of S1P mediated by lipid phosphate phosphatases, S1P phosphatases, and S1P lyase. We and othershave demonstratedthatS1P is a potent angiogenic factor that enhances lung endothelial cell integrity and an inhibitor of vascular permeability and alveolar flooding in preclinical animal models of ALI. In addition to S1P, S1P analogues such as 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720), FTY720 phosphate, and FTY720 phosphonates offer therapeutic potential in murine models of lung injury. This translational review summarizes the roles of S1P, S1P analogues, S1P-metabolizing enzymes, and S1P receptors in the pathophysiology of lung injury, with particular emphasis on the development of potential novel biomarkers and S1P-based therapies for ALI and RILI.

KW - S1P lyase

KW - S1P receptors

KW - Sepsis

KW - Sphingolipids

KW - Sphingosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84883176854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883176854&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2012-0411TR

DO - 10.1165/rcmb.2012-0411TR

M3 - Article

C2 - 23449739

AN - SCOPUS:84883176854

VL - 49

SP - 6

EP - 17

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 1

ER -